Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

119Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Purpose: A phase I study with topotecan (SKF 104864-A, NSC 609699), a semisynthetdc analog of camptothecin, was performed using a daily-times-5 regimen, given i.v. q 3 weeks, to evaluate the pharmacokinetics and toxicities of the compound.Patients and methods: Patients with a histologically confirmed diagnosis of a solid tumor no longer amenable to established forms of treatment were eligible for the study. Topotecan was given as a 30 min. infusion daily on 5 successive days, repeated every three weeks. In subsequent patient cohorts the dose was escalated from 0.5 to 1.5 mg/m2/ day. Weekly evaluations included hematology and biochemistry. Response to treatment was assessed every 2 cycles. Pharmacokinetics were performed using a HPLC method.Results: Forty-eight patients were entered. The maximal tolerated dose was 1.5 mg/m2day. The dose limiting toxicity was leucocytopenia. Other major toxicities were alopecia and moderate nausea/vomiting. Partial remissions were observed in one patient with pretreated small-cell lung cancer, one with non-small-cell lung cancer and one with no-pretreated pancreatic cancer, lasting 130-240 days. Pharmacokinetics showed a t2-Jan(α) of 8.1 ± 7.6 min, t2-Jan(β) of 132 ± 48 min, Vd, ss 72.7 ± 26.9 L/m2 and Clwt, of 0.57 ± 0.16 L/min/m2.Conclusion: Topotecan is an interesting new topoisomerase I inhibitor exerting antitumor activity in this phase I trial. Leucocytopenia is dose-limiting. The recommended dose for phase II studies is 1.5 mg/m2/day for 5 consecutive days every 3 weeks. © 1993 Kluwer Academic Publishers.

Cite

CITATION STYLE

APA

Verweij, J., Lund, B., Beijnen, J., De Boer-dennert, M., Koier, I., Rosing, H., & Hansen, H. (1993). Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Annals of Oncology, 4(8), 673–678. https://doi.org/10.1093/oxfordjournals.annonc.a058623

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free